Sign up to get each new magazine issue delivered to your inbox
Next Issue
October 2022
Previously considered to be an undruggable target, KRAS came to the forefront when the first positive clinical data with two KRAS G12C inhibitors was presented in June 2019. Now, as new data emerges on combination treatments, their reach in oncology is only expected to grow. In next month’s issue, we chart the journey for these drugs that are expected to yield over a billion dollars.
Also, we continue our series on Orphan Drug designations with a look at the rare conditions with the most investigational drugs that have made use of this program.
All this plus the latest trends and innovations in the pharma industry, as well as up-to-date analysis and insight from GlobalData experts.
EDITORIAL
Editor | Manasi Vaidya
Writers | Akosua Mireku, Adam Zamecnik, Andrew Hillman, Manasi Vaidya, Urtė Fultinavičiūtė
Magazine Designer | Will Ingham
Graphic Designers | Anett Arc, Ashley McPherson, Martina Labaiova, Noemi Balint, Tyrrell Lowe
Lead Designer | John Hammond
Publisher | Susanne Hauner
Advertising
Sales Manager | Tom McCormick
+44 207 8669440
Cover image credit: Ink Drop/ Shutterstock.com
Pharma Technology Focus is powered by H5mag
Read past issues of Pharma Technology Focus HERE
Copyright 2022 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.